2020
Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs
Shrestha R, DiDomizio EE, Kim RS, Altice FL, Wickersham JA, Copenhaver MM. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. Journal Of Substance Use And Addiction Treatment 2020, 117: 108058. PMID: 32811633, PMCID: PMC7438607, DOI: 10.1016/j.jsat.2020.108058.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisInjectable pre-exposure prophylaxisLAI-PrEPOral pre-exposure prophylaxisLong-term side effectsSelf-reported HIV risk behaviorsBangkok Tenofovir StudyEvidence-based HIVHigh-risk PWUDImportant key populationHIV-negative peopleOpioid use disorderHIV risk behaviorsHIV prevention effortsAddiction treatment programsDaily PrEPOral PrEPAdherence challengesIndependent correlatesFemale sexClinical trialsHIV preventionIndependent factorsSide effectsUse disorders
2018
Viral suppression among HIV-infected methadone-maintained patients: The role of ongoing injection drug use and adherence to antiretroviral therapy (ART)
Shrestha R, Copenhaver MM. Viral suppression among HIV-infected methadone-maintained patients: The role of ongoing injection drug use and adherence to antiretroviral therapy (ART). Addictive Behaviors 2018, 85: 88-93. PMID: 29879611, PMCID: PMC6337064, DOI: 10.1016/j.addbeh.2018.05.031.Peer-Reviewed Original ResearchConceptsMethadone maintenance therapyMethadone-maintained patientsOngoing injection drug useViral suppressionAntiretroviral therapyInjection drug useHIV risk behaviorsDrug useSelf-reported HIV risk behaviorsImproved virologic outcomesOptimal ART adherenceHigher CD4 countsSustained viral suppressionMultivariable logistic regressionVirologic outcomesCD4 countMaintenance therapyOptimal adherenceART adherenceHIV treatmentIndependent correlatesTreatment challengesRisk populationsPatientsHIV